Nature Reviews Cancer 12, 89–103 (2012)
In the legend to Figure 6c, the distribution according to therapeutic strategy (monotherapy versus combined therapy) involving HGF/SF–MET monotherapies should have read 44%. This has been corrected on both html and pdf versions.
Additional information
The online version of the original article can be found at 10.1038/nrc3205
Rights and permissions
About this article
Cite this article
Gherardi, E., Birchmeier, W., Birchmeier, C. et al. Erratum: Targeting MET in cancer: rationale and progress. Nat Rev Cancer 12, 637 (2012). https://doi.org/10.1038/nrc3367
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrc3367
